Meta-analysis comparing the efficacy and adverse events of biologics and thiopurines for Crohn's Disease after surgery for ulcerative colitis. Issue 10 (October 2018)

• Record Type: Journal Article
• Authors: Yadav, Abhijeet; Kurada, Satya; Foromera, Joshua; Falchuk, Kenneth R.; Feuerstein, Joseph D.
• Is Part Of: Digestive and liver disease. Volume 50:Issue 10(2018)
• Page Start: 1004
• Page End: 1011
• Publication Date: 2018-10
• Subjects: Anti-TNF therapy -- Crohn's Disease -- Ileal pouch anal anastomosis -- Immunomodulator -- Ulcerative colitis; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2018.05.017
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Long-term inflammatory complications of IPAA include Crohn's Disease (CD) or "CD-like" (CDL) condition. We performed a meta-analysis to evaluate the efficacy of anti-tumor necrosis factor (anti-TNF) with or without immunomodulator (IM) therapy in this group of patients. Methods: Literature databases were searched from inception to October 4, 2017. Further searches using references from papers of interest were conducted and, abstracts from major GI conferences were searched. The primary endpoint was: complete clinical response in the two arms. Results: Out of 9 identified studies 4 were included for quantitative analysis. 48% (84/175) were female and mean age was 30.7 years. There was no significant difference in complete clinical response rates, RR 0.58 (95%CI 0.13–2.54, p = 0.5) or partial clinical response rates of RR 0.98 (95%CI 0.52–1.83, p = 0.94). All patients achieved endoscopic and deep remission in the only study reporting these outcomes comparatively in the two arms. There was a trend towards higher risk of major [RR 3.89, (95%C 0.92–16.45 p = 0.09)], and minor adverse events [RR 3.07 (95%CI 0.7–13.52 p = 0.28)] when using anti-TNF therapy compared to anti-TNF with IM. Conclusion: We found no difference in outcomes with anti-TNF monotherapy compared to concurrent anti-TNF therapy with IM. Additional studies are needed to define the optimal therapy for CD after IPAA.